Skip to main content
Log in

Polymorphic 4-hydroxylation of debrisoquine in chronic discoid psoriasis

  • Short Communication
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

1. The 4-hydroxylation of debrisoquine was measured in 42 patients with chronic discoid psoriasis. 2. The proportion of poor metabolisers (4.8%) and the median metabolic ratio (0.5) in psoriatics were similar to that reported previously in a healthy British population. 3. We conclude that the abnormality of microsomal mono-oxygenase activity which we have found in the skin and other tissues of psoriatics is not due to a generalised (non-specific) impairment of microsomal oxidation and may be enzyme specific.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Alvares AP, Kappas A, Levin W, Conney AH (1973) Inducibility of benz(α)pyrene hydroxylase in human skin by polycyclic hydrocarbons. Clin Pharmacol Ther 14: 30–40

    Google Scholar 

  2. Chapman PH, Rawlins MD, Shuster S (1979) The activity of aryl hydrocarbon hydroxylase in adult human skin. Br J Clin Pharmacol: 499–503

  3. Chapman PH, Rawlins MD, Shuster S (1979) The activity of aryl hydrocarbon hydroxylase in psoriatic skin. Lancet 1: 297–298

    Google Scholar 

  4. Chapman PH, Rawlins MD, Shuster S, Rogers S (1979) Impaired epidermal microsomal AHH activity in discoid and pustular psoriasis. J Invest Dermatol 72: 267–268

    Google Scholar 

  5. Shuster S, Rawlins MD, Chapman PH, Rogers S (1980) Decreased epidermal AHH and localised pustular psoriasis. Br J Dermatol 103: 23–26

    Google Scholar 

  6. Chapman PH, Kersey PJ, Keys B, Shuster S, Rawlins MD (1980) Generalised tissue abnormality of aryl hydrocarbon hydroxylase in psoriasis. Br Med J 281: 1315–1315

    Google Scholar 

  7. Chapman PH, Moss C, Keys B, Shuster S, Rawlins MD (1981) Antipyrine clearance in psoriasis. Br Med J 282: 20–21

    Google Scholar 

  8. Idle PJ, Mahgoub A, Angelo MM, Dring LG, Lancaster R, Smith RL (1979) The metabolism of14C-debrisoquine in man. Br J Clin Pharmacol 7: 257–266

    Google Scholar 

  9. Danhof M, Breimer DD (1979) Studies on the different metabolic pathways of antipyrine in man. 1. Oral administration of 250, 500 and 1000 mg to healthy volunteers. Br J Clin Pharmacol 8: 529–537

    Google Scholar 

  10. Rogers S, Marks J, Shuster S, Briffa DV, Warin A, Greaves M (1979) Comparison of photochemotherapy and dithranol in the treatment of chronic plaque psoriasis. Lancet 1: 455–458

    Google Scholar 

  11. Price Evans DA, Mahgoub A, Sloan TP, Idle JR, Smith RL (1980) A family and population study of the genetic polymorphism of debrisoquine oxidation in the British white population. J Med Genet 17: 102–105

    Google Scholar 

  12. Mahgoub A, Idle JR, Dring LG. Lancaster R, Smith RL (1977) Polymorphic hydroxylation of debrisoquine in man. Lancet 2: 584–586

    Google Scholar 

  13. Shuster S, Chapman PH, Rawlins MD (1979) Psoriasis and Cancer. Br Med J 1: 941–942

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chapman, P.H., Rawlins, M.D., Shuster, S. et al. Polymorphic 4-hydroxylation of debrisoquine in chronic discoid psoriasis. Eur J Clin Pharmacol 21, 257–258 (1981). https://doi.org/10.1007/BF00627929

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00627929

Key words

Navigation